Ruscogenin – 10 mg

Brand:
Cayman
CAS:
472-11-7
Storage:
-20
UN-No:
Non-Hazardous - /

Ruscogenin is a steroid sapogenin that has been found in O. japonicus with diverse biological activities.{43257,43258,43259,43260,43261} It reduces adhesion of HL-60 cells to ECV304 cells induced by phorbol 12-myristate 13-acetate (PMA; Item No. 10008014) with an IC50 value of 7.76 nM and decreases peritoneal leukocyte migration induced by zymosan A (Item No. 21175) in mice when administered at a dose of 5 mg/kg.{43257} Oral administration of ruscogenin (12.5 mg/kg) inhibits ADP-induced platelet aggregation in rats.{43258} Ruscogenin prevents monocrotaline-induced increases in mean arterial pressure (MAP), expression of IL-1β and TNF in plasma and lung, and endothelial cell apoptosis in pulmonary arterioles in a rat model of pulmonary hypertension.{43259} It also reduces proteinuria and renal macrophage infiltration in a rat model of diabetes induced by streptozotocin (Item No. 13104) and decreases gene expression of inflammatory cytokines, dyslipidemia, and liver steatosis in a hamster model of high-fat diet-induced nonalcoholic steatohepatitis (NASH).{43260,43261}  

 

Available on backorder

SKU: 25217 - 10 mg Category:

Description

A steroid sapogenin with diverse biological activities; reduces PMA-induced adhesion of HL-60 cells to ECV304 cells (IC50 = 7.76 nM); decreases zymosan A-induced peritoneal leukocyte migration in rats at 5 mg/kg; inhibits ADP-induced platelet aggregation in rats at 12.5 mg/kg; prevents monocrotaline-induced increases in MAP, expression of IL-1β and TNF in plasma and lung, and endothelial cell apoptosis in pulmonary arterioles in a rat model of pulmonary hypertension; reduces proteinuria and renal macrophage infiltration in a rat model of streptozotocin-induced diabetes; decreases gene expression of inflammatory cytokines, dyslipidemia, and liver steatosis in a hamster model of high-fat diet-induced NASH


Formal name: (1β,3β,25R)-spirost-5-ene-1,3-diol

Synonyms: 

Molecular weight: 430.6

CAS: 472-11-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Natural Products|Saponins||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Immunology & Inflammation|Innate Immunity